Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$6.94
<$0.01(0.02%)
At close: 4:00 PM EST
$6.94
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$4.50 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)87.53K
Market Cap
$150.46M
Enterprise Value$49.50M
Total Cash (Recent Filing)$54.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 26, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding21,774,103
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue4.57
Enterprise Value/Gross Profit5.30
Enterprise Value/Ebitda-1.83
Forecast
1Y Price Target
$15.00Price Target Upside116.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$22.77M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Rapid Revenue GrowthAlpha Cognition shows durable top-line traction with TTM revenue up ~5.9x and an ~87% gross margin, indicating very favorable unit economics. High gross margins create scalable operating leverage as volumes grow, improving prospects for sustainable profitability if commercial expansion continues.
Debt-free Balance Sheet With Meaningful EquityA debt-free balance sheet and meaningful equity reduce refinancing and liquidity risk, giving management flexibility to fund commercialization and clinical programs. This structural financial strength supports multi-quarter execution on milestones without immediate debt pressure, enhancing strategic optionality.
Commercial Infrastructure And Repeat UtilizationA fully staffed 60-person commercial team, combined with high repeat usage (~75% of writers placing repeat scripts), signals durable go-to-market capability and product stickiness. This sales infrastructure plus AI-enabled analytics supports scalable prescriber engagement and sustained market penetration over many quarters.
Bears Say
Significant Cash Burn And Limited Runway RiskThe company is burning substantial cash (TTM OCF and FCF ≈ -$30M), and cash declined from $66.0M to $54.2M in Q1. Continued negative cash flow requires external financing or material revenue scale; sustained burn elevates dilution or execution risk if commercial growth or funding events slow.
Limited Downstream Payer Implementation; Data-dependencyWhile PBM contracts cover many lives, only ~16% downstream implementation limits patient access. Commercial scaling relies on upcoming datasets (BEACON, CONVERGE) to expand coverage; unfavorable or delayed results would structurally constrain adoption and revenue growth over the medium term.
Large Ongoing Losses And Negative Operating LeverageVery negative margins (TTM net margin ~-172%) and rising quarterly losses reflect operating costs far exceeding current scale. Without sustained revenue acceleration or meaningful operating leverage, profitability targets will be hard to meet and the company will remain reliant on capital markets to fund growth.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $150.46M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Aug 26, 2026 which is in 66 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on May 14, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.387 by $0.067.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.4.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,774,103 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.387. Following the earnings report the stock price went up 5.986%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (116.14% Upside)
$15.00 (116.14% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
-54.13%
Trailing 12-Months
Asset Growth
42.46%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm focused on creating therapies for neurological conditions such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Among its offerings is ZUNVEYL (benzgalantamine), intended for the management of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. The company is also progressing with other therapeutic programs, including ALPHA-0602, a gene therapy specifically for ALS, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs targeting various neurodegenerative disorders. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before rebranding to Alpha Cognition Inc. in March 2021. Its corporate base is located in Vancouver, Canada.
ACOG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong early commercial trajectory for ZUNVEYL with clear sequential growth in revenue (40% QoQ), accelerating prescription metrics (bottles +23% QoQ, prescriber calls +93% QoQ) and multiple near-term clinical and IP catalysts (BEACON, CONVERGE, sublingual PK, two patents to 2045). Management is deliberately investing in a 60-person commercial team, payer engagement, and real-world evidence generation to drive broader access and expects operating profitability in 2027. Offsetting these positives are meaningful near-term challenges: increased net losses and operating spend, cash decline, limited downstream PBM implementation (~16% of book), and reliance on upcoming data to expand payer coverage. Overall the call was upbeat and progressing toward commercialization scale, but the company remains in an investment phase with execution and payer adoption as key near-term risks.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$15.00
▲(116.14% Upside)
Technical Analysis
Sangamo Therapeutics
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
18.30% Insiders
0.06% Mutual Funds
46.29% Other Institutional Investors
35.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---